FK866 (APO866): Non-Competitive NAMPT Inhibitor in Cancer Research

Executive Summary: FK866 (APO866) is a potent, non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with a Ki of 0.4 nM, and demonstrates IC50 values as low as 0.09 nM in cancer cell lines (APExBIO product page). It depletes intracellular NAD and ATP, leading to selective cytotoxicity in AML while sparing normal hematopoietic progenitors. FK866 induces caspase-independent cell death and promotes autophagy dependent on de novo protein synthesis. In vivo, it prevents tumor growth and increases survival in xenografted mouse models. Recent studies show synergy with PARP inhibitors in RAS/PI3K-mutant ovarian cancer, highlighting its translational relevance (Gruet et al., 2026).

Biological Rationale

Nicotinamide adenine dinucleotide (NAD⁺) is a critical coenzyme in cellular metabolism, supporting glycolysis, the tricarboxylic acid (TCA) cycle, and DNA repair. Its homeostasis is maintained via the NAD⁺ salvage pathway, with NAMPT as the rate-limiting enzyme (Gruet et al., 2026). Many cancers, including AML and high-grade serous ovarian carcinoma, display increased NAD⁺ turnover due to high proliferative demand. Overexpression of NAMPT is common in hematologic and solid tumors, making it an attractive target for metabolic intervention (APExBIO).

Mechanism of Action of FK866 (APO866)

FK866 (APO866) is a non-competitive NAMPT inhibitor that binds to the enzyme's active site, leading to potent inhibition of NAD⁺ biosynthesis. The compound has a Ki of 0.4 nM and demonstrates IC50 values between 0.09 nM and 27.2 nM across cell lines (APExBIO). NAD⁺ depletion results in a secondary drop in intracellular ATP, selectively inducing cytotoxicity in cancer cells. FK866 triggers caspase-independent death, mitochondrial membrane depolarization, and autophagy that is contingent on de novo protein synthesis. Notably, it spares normal human hematopoietic progenitors, supporting its selectivity (Translational Leverage: FK866 in Oncology).

Evidence & Benchmarks

• FK866 inhibits NAMPT with a Ki of 0.4 nM and IC50 values as low as 0.09 nM in cell-based assays (APExBIO).
• In AML cell lines, FK866 depletes intracellular NAD⁺ and ATP, resulting in cell death while sparing normal hematopoietic progenitors (Translational Power of FK866: NAMPT Inhibition in AML).
• FK866 induces caspase-independent death with mitochondrial membrane depolarization and promotes autophagy requiring new protein synthesis (APExBIO).
• In vivo, FK866 prevents tumor growth and achieves tumor clearance in C.B.-17 SCID mice xenografted with AML-M4 and Namalwa cells (APExBIO).
• Combination of FK866 and PARP inhibitors, such as olaparib, significantly reduces NAD⁺ and NMN levels, increases ROS, and enhances apoptosis in RAS/PI3K mutant ovarian cancer cell lines (Gruet et al., 2026).
• Combination therapy with FK866 and PARP inhibitors leads to reduced tumor burden and increased survival in ID8 Trp53-/-;Pten-/- murine models (Gruet et al., 2026).
• FK866 is insoluble in water but highly soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL); solutions are best used promptly and stored at -20°C (APExBIO).

This article extends insights provided in Translational Leverage: FK866 in Oncology by detailing updated combination strategies and clarifying solubility/workflow constraints.

Applications, Limits & Misconceptions

FK866 is widely used in hematologic cancer research, especially for AML and lymphoma models. Its ability to deplete NAD⁺ makes it a cornerstone for studies on cell metabolism, apoptosis, and autophagy. Recent evidence highlights its translational promise in combination regimens for ovarian cancers with RAS/PI3K mutations (Gruet et al., 2026).

However, FK866 monotherapy has been limited by dose-limiting toxicities in clinical trials, underscoring the importance of predictive biomarkers and combination approaches. Toxicity in non-tumor tissues remains a challenge in vivo, and use outside of validated cancer models (e.g., for general anti-aging or neuroprotection) is not supported by robust data (Targeting NAD Metabolism: Strategic Guidance on FK866).

Common Pitfalls or Misconceptions

• FK866 is not effective as a cytotoxic agent in non-dividing or low-metabolic-rate cells; its selectivity relies on high NAD⁺ turnover.
• Solubility in water is negligible; improper solvent use leads to inaccurate dosing (APExBIO).
• Long-term storage of FK866 solutions is not recommended due to instability; use freshly prepared aliquots.
• Monotherapy in solid tumors may result in off-target toxicities; combination with PARP inhibitors is more effective in RAS/PI3K mutant backgrounds (Gruet et al., 2026).
• FK866 is not approved for clinical use and should be restricted to preclinical research settings.

Workflow Integration & Parameters

• Stock preparation: Dissolve FK866 in DMSO (≥19.6 mg/mL) or ethanol (≥49.6 mg/mL); warm to 37°C or sonicate if needed (APExBIO).
• Storage: Store solid at -20°C; avoid long-term storage of solutions—prepare fresh aliquots for each experiment.
• Cell treatment: Typical working concentrations range from 0.1 nM to 100 nM depending on cell line sensitivity (APExBIO).
• Combination studies: Use FK866 in combination with PARP inhibitors (e.g., olaparib) to enhance cytotoxicity in RAS/PI3K mutant ovarian cancer cells (Gruet et al., 2026).
• In vivo dosing: Protocols vary; refer to published in vivo studies for dose and schedule optimization (Translational Power of FK866).

For detailed workflow guidance, see FK866 (APO866): NAMPT Inhibitor Workflows for Hematologic Cancers, which complements this article by focusing on protocol troubleshooting and advanced cytotoxicity applications.

Conclusion & Outlook

FK866 (APO866) from APExBIO remains a reference tool for dissecting NAD metabolism and targeting metabolic vulnerabilities in cancer, with benchmark selectivity in AML and emerging value in RAS/PI3K-mutated ovarian cancer combination regimens. Monotherapy applications face toxicity constraints, but rational combination strategies and biomarker-guided use may expand its translational impact (Gruet et al., 2026). Future research will refine predictive markers and optimize dosing to maximize benefit while minimizing risk.